JP2022538894A5 - - Google Patents

Info

Publication number
JP2022538894A5
JP2022538894A5 JP2021578065A JP2021578065A JP2022538894A5 JP 2022538894 A5 JP2022538894 A5 JP 2022538894A5 JP 2021578065 A JP2021578065 A JP 2021578065A JP 2021578065 A JP2021578065 A JP 2021578065A JP 2022538894 A5 JP2022538894 A5 JP 2022538894A5
Authority
JP
Japan
Prior art keywords
wild
residue
type human
human neu2
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021578065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538894A (ja
JP7777988B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040828 external-priority patent/WO2021003469A2/en
Publication of JP2022538894A publication Critical patent/JP2022538894A/ja
Publication of JP2022538894A5 publication Critical patent/JP2022538894A5/ja
Priority to JP2025197401A priority Critical patent/JP2026032063A/ja
Application granted granted Critical
Publication of JP7777988B2 publication Critical patent/JP7777988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021578065A 2019-07-03 2020-07-03 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 Active JP7777988B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025197401A JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870403P 2019-07-03 2019-07-03
US62/870,403 2019-07-03
US202062957011P 2020-01-03 2020-01-03
US62/957,011 2020-01-03
PCT/US2020/040828 WO2021003469A2 (en) 2019-07-03 2020-07-03 Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025197401A Division JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022538894A JP2022538894A (ja) 2022-09-06
JP2022538894A5 true JP2022538894A5 (cg-RX-API-DMAC7.html) 2023-07-10
JP7777988B2 JP7777988B2 (ja) 2025-12-01

Family

ID=74101301

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578065A Active JP7777988B2 (ja) 2019-07-03 2020-07-03 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法
JP2025197401A Pending JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025197401A Pending JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Country Status (9)

Country Link
US (1) US20220356457A1 (cg-RX-API-DMAC7.html)
EP (1) EP3994275A4 (cg-RX-API-DMAC7.html)
JP (2) JP7777988B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220032576A (cg-RX-API-DMAC7.html)
CN (1) CN114258431A (cg-RX-API-DMAC7.html)
AU (1) AU2020301037B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026789A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145676A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021003469A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
AU2020301037B2 (en) * 2019-07-03 2026-08-06 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
CN114302897A (zh) * 2019-07-03 2022-04-08 帕利昂制药有限公司 唾液酸酶-her2抗体融合蛋白及其使用方法
MX2022000032A (es) * 2019-07-03 2022-06-15 Palleon Pharmaceuticals Inc Sialidasas recombinantes y métodos de utilización de las mismas.
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法
WO2025217138A1 (en) * 2024-04-09 2025-10-16 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
EP4744681A1 (en) 2024-08-16 2026-05-20 Shanghai Bao Pharmaceuticals Co., Ltd. COMPLEX TARGETING TARGET CELLS AND ITS USE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026908A1 (en) * 1993-05-17 1994-11-24 Genentech, Inc. Cho cell sialidase by recombinant dna technology
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
WO2007108464A1 (ja) * 2006-03-20 2007-09-27 Kyowa Hakko Kogyo Co., Ltd. 哺乳動物由来細胞質シアリダーゼに対する抗体
CN100376689C (zh) * 2006-03-28 2008-03-26 北京大学 一种预测达菲类药物用药安全性的方法
DK2195444T3 (en) * 2007-10-12 2015-08-24 Sigma Aldrich Co Llc Cell line and methods for enhanced sialylation of glycoprotein.
BRPI1015234A2 (en) * 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
AU2010315024B2 (en) * 2009-11-06 2015-02-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
WO2014167112A1 (en) * 2013-04-12 2014-10-16 Danmarks Tekniske Universitet A mutant sialidase having trans-sialidase activity for use in production of sialylated glycans
US20190300606A1 (en) * 2016-07-01 2019-10-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory Immune Receptor Inhibition Methods and Compositions
ES2947312T3 (es) 2016-07-01 2023-08-04 Univ Leland Stanford Junior Conjugados para la edición dirigida de la superficie celular
EP3630968B8 (en) 2017-05-26 2024-07-03 Genovis AB Enzymes for glycan analysis
JP7462560B2 (ja) * 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
US20250049846A1 (en) * 2019-01-03 2025-02-13 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells
AU2020301037B2 (en) * 2019-07-03 2026-08-06 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Similar Documents

Publication Publication Date Title
JP2023532021A5 (cg-RX-API-DMAC7.html)
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP2024501771A5 (cg-RX-API-DMAC7.html)
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2024501767A5 (cg-RX-API-DMAC7.html)
RU2011138951A (ru) Пропротеины и способы их применения
SG193860A1 (en) Fgf21 mutants and uses thereof
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
US20240228586A1 (en) Compositions and methods comprising protease-activated therapeutic agents
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
KR20240035556A (ko) 융합 폴리펩타이드를 이용하는 프로테아제 매개성의 표적 특이적 사이토카인 송달
JP2023535695A5 (cg-RX-API-DMAC7.html)
EP3944877A1 (en) Nanobodies sars-cov2
CA3145676A1 (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
CN104292331B (zh) 人源抗人α干扰素抗体及其应用
WO2021247675A1 (en) Coronavirus-binding agents and uses thereof
JP2023551194A5 (cg-RX-API-DMAC7.html)
JP2024501770A5 (cg-RX-API-DMAC7.html)
KR20200011685A (ko) 갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도
WO2024017281A1 (zh) 多特异性抗体及其用途
US11401309B2 (en) Protein M fusion proteins and uses
US20090226942A1 (en) Modified aerolysin and methods of use for treating lung cancer
JP2024523290A5 (cg-RX-API-DMAC7.html)
KR20210119421A (ko) 탈면역화된 시가 독소 a 서브유닛 이펙터를 포함하는 cd38-결합 단백질(cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors)
JP2024542235A5 (cg-RX-API-DMAC7.html)